Intercept Pharmaceuticals
ICPTUnlisted companyIntercept Pharmaceuticals in brief
Intercept Pharmaceuticals is an unlisted company in the Biotechnology industry, based in New York, USA. It was founded in 2002. In the year to December 2022 it had sales of $286 M and a net profit of $222 M, about 78 cents of profit for every dollar of sales. It employs about 437 people.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Intercept Pharmaceuticals timeline
- 2002
- 🏁· approximateFounded
- 2003
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- 🔔· approximateInitial public offering on Nasdaq
- 2022
- 💰Record revenue of $286 millionFY2022, the highest of the 5 years on record.
Events of Intercept Pharmaceuticals from Wikidata, SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Intercept Pharmaceuticals
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 8 November 2023 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #1,043 (Jan 2020) · #2,364 (Jan 2021) · #3,043 (Jan 2022) · #2,620 (Dec 2022) · #2,796 (Jul 2023)
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 77.6%
- Operating margin
- -23.9%
- Return on equity
- 238.3%
- Liabilities / assets
- 83.2%
- Net debt
- $173M
- Revenue growth
- +9.6%
- R&D / revenue
- 61.8%
- Revenue per employee
- $654 K
- Profit per employee
- $508 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2022 | $286M | +9.6% | $-68M | $222M | 77.6% |
| Dec 2021 | $261M | +11.4% | $-100M | $-91M | -35.1% |
| Dec 2020 | $234M | -7.2% | $-230M | $-275M | -117.5% |
| Dec 2019 | $252M | +40.2% | $-312M | $-345M | -136.8% |
| Dec 2018 | $180M | +37.3% | $-285M | $-309M | -172.0% |
| Dec 2017 | $131M | +424.9% | $-336M | $-360M | -275.2% |
| Dec 2016 | $25M | +797.5% | $-403M | $-413M | -1654.6% |
| Dec 2015 | $3M | — | $-229M | $-226M | -8145.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2022 | $-27M | $1M | $-27M | $6.56 | — |
| Dec 2021 | $-41M | $0M | $-41M | $-2.87 | — |
| Dec 2020 | $-172M | $4M | $-176M | $-8.34 | — |
| Dec 2019 | $-237M | $1M | $-238M | $-10.89 | — |
| Dec 2018 | $-241M | $0M | $-241M | $-10.86 | — |
| Dec 2017 | $-265M | $10M | $-276M | $-14.38 | — |
| Dec 2016 | $-342M | $5M | $-348M | $-16.74 | — |
| Dec 2015 | $-163M | $6M | $-169M | $-9.56 | — |
Quarterly results
Latest quarter to Sep 2023: revenue $89M, net income $-3M. Trailing 12 months to Dec 2022.
SEC filings
- Nov 8, 20238-KCurrent reportMaterial agreement · Acquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended · Other events
- Nov 6, 202310-QQuarterly report · period to Sep 2023
- Sep 26, 20238-KCurrent reportMaterial agreement · Other events
- Aug 2, 202310-QQuarterly report · period to Jun 2023
- Aug 2, 20238-KCurrent reportResults of operations
- Jun 23, 20238-KCurrent reportRestructuring costs · Regulation FD disclosure
- Jun 23, 20238-KCurrent reportRegulation FD disclosure
- May 25, 20238-KCurrent reportShareholder vote
- May 22, 20238-KCurrent reportRegulation FD disclosure
- May 18, 20238-KCurrent reportMaterial agreement · Other events
- May 1, 2023DEF 14AProxy statement
- Apr 27, 202310-QQuarterly report · period to Mar 2023
Official filings of Intercept Pharmaceuticals with the US Securities and Exchange Commission.
Annual results
- Revenue
- $286 M
- Operating income
- $-68 M
- Net income
- $222 M
For year ending December-2022 · source: SEC filing
Balance sheet
- Total assets
- $554 M
- Total liabilities
- $461 M
- Total equity
- $93 M
As of December-2022
Insider trading at Intercept Pharmaceuticals#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jerome Benedict DursoCEO, Director | Tender in a change of control | -51,815 | $19.00 | $984 K | 0 | Form 4 |
| filed | Keith Michael GottesdienerDirector | Tender in a change of control | -24,719 | $19.00 | $470 K | 0 | Form 4 |
| filed | Dagmar Rosa-BjorkesonDirector | Tender in a change of control | -14,766 | $19.00 | $281 K | 0 | Form 4 |
| filed | Glenn SblendorioDirector | Tender in a change of control | -23,447 | $19.00 | $445 K | 0 | Form 4 |
| filed | M. Michelle BerreyPresident, R&D and CMO | Tender in a change of control | -28,349 | $19.00 | $539 K | 0 | Form 4 |
| filed | Paolo FundaroDirector | Tender in a change of control | -35,794 | $19.00 | $680 K | 0 | Form 4 |
| filed | Gino SantiniDirector | Tender in a change of control | -23,645 | $19.00 | $449 K | 0 | Form 4 |
| filed | Srinivas AkkarajuDirector | Tender in a change of control | -37,887 | $19.00 | $720 K | 0 | Form 4 |
Markets and events: Intercept Pharmaceuticals#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 5.778-for-1 split
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2021 | Q4 2021 | $0M |
Intercept Pharmaceuticals scorecard#
Passes 8 of the 15 checks that could be worked out: strongest in profitability (3 of 4), weakest in financial health (1 of 4). Fiscal year 2022.
Valuationnot known
Growth4 of 6
Profitability3 of 4
Financial health1 of 4
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Intercept Pharmaceuticals: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 | FY 2014to Dec 31, 2014 | FY 2013to Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 286 | 261r | 234r | 252 | 180 | 131 | 25 | 2.8 | 1.7 | — | |
| Cost of revenue | 1.0 | 1.2r | 2.4r | 4.2 | 2.5 | 1.4 | — | — | — | — | |
| Research and development | 177 | 183r | 189r | 243 | 207 | 191 | 154 | 113r | 80r | 28r | |
| Selling, general and administrative | 176 | 177r | 261r | 317 | 255 | 274 | 274 | 119 | 35 | — | |
| General and administrative | — | — | — | — | — | — | — | 104 | 35r | 13r | |
| Operating expenses | — | — | — | — | 465 | 467 | 427 | 232 | 115 | — | |
| Total costs and expenses | 354 | 361r | 464r | 564 | 465 | 467 | — | 232 | 115r | 41r | |
| Operating income | −68 | −100r | −230r | −312 | −285 | −336 | −403 | −229 | −113 | — | |
| Interest expense and finance costs | 21 | 54 | 48 | 41 | 31 | 29 | 14 | — | — | — | |
| Other non-operating income (expense) | −107 | −36r | −44r | −32 | −24 | −25 | −10 | 2.7 | −170r | −28r | |
| Income before tax | −175 | −136r | −273r | −345 | −309 | −360 | −413 | −226 | −283 | −68 | |
| Income from discontinued operations | 397 | 45 | −1.5 | — | — | — | — | — | — | — | |
| Net income including minority interests | 222 | −91 | −275 | −345 | −309 | −360 | −413 | — | — | — | |
| Net income attributable to shareholders | 222 | −91 | −275 | −345 | −309 | −360 | −413 | −226 | −283r | −68r | |
| Earnings per share, basic | 6.56 | -2.87 | -8.34 | -10.89 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | |
| Earnings per share, diluted | 6.56 | -2.87 | -8.34 | -10.89 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | |
| Shares, weighted average (basic) | 34 | 32 | 33 | 32 | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 34 | 32 | 33 | 32 | 28 | 25 | 25 | 24r | 21r | 18 | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 51 | 85 | 58r | 70r | 43 | 70 | 44 | 33 | 20r | 13r | |
| Short-term investments | — | — | 412 | 583 | 393 | — | — | — | — | — | |
| Receivables | 27 | 28r | 42 | 38 | 26 | 17 | 9.1 | — | — | — | |
| Inventory | 6.5 | 7.9r | 9.0 | 8.5 | 7.1 | 3.5 | 2.3 | — | — | — | |
| Other current assets | 22 | 23r | 27 | 26 | 21 | 17 | 9.4 | 14 | 6.1r | 2.7 | |
| Current assets | 540 | 508r | 546 | 721 | 482 | 448 | 708 | 642 | 246r | 148 | |
| Property, plant and equipment | 1.0 | 3.3r | 6.3 | 5.2 | 10 | 16 | 11 | 10 | 5.9r | 1.7 | |
| Right-of-use (leased) assets | — | 6.1 | 12 | 13 | — | — | — | — | — | — | |
| Total assets | 554 | 527 | 580 | 755 | 509 | 484 | 739 | 656 | 254r | 150 | |
| Accounts payable | 14 | 18r | 25 | 19 | 12 | 7.0 | 6.7 | 4.2 | 3.1 | 3.2 | |
| Debt due within a year | 110 | 0 | — | — | — | — | — | — | — | — | |
| Current liabilities | 230 | 168r | 179 | 162 | 114 | 104 | 79 | 47 | 15r | 8.9 | |
| Long-term debt | 223 | 540 | 561 | 532 | 371 | 356 | 341 | — | — | — | |
| Lease liabilities (non-current) | — | 4.4 | 7.7 | 9.2 | — | — | — | — | — | — | |
| Total liabilities | 461 | 711 | 747 | 703 | 490 | 468 | 424 | 54 | 23r | 68 | |
| Retained earnings | −2,137 | −2,490 | −2,398 | −2,123 | −1,779 | −1,470 | −1,108 | −696 | −469r | −186 | |
| Shareholders' equity | 93 | −184 | −167 | 52 | 19 | 16 | 315 | 602 | 231r | 82r | |
| Total liabilities and equity | 554 | 527 | 580 | 755 | 509 | 484 | 739 | 656 | 254r | 150 | |
| Shares outstanding | 42 | 30 | 33 | 33 | 30 | 25 | 25 | 24 | 21 | 19 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 0.4 | 0.1 | |
| Share-based compensation | 22 | 28r | 49r | 56 | 50 | 57 | 46 | 34 | 20r | 9.4r | |
| Cash from operating activities | −27 | −41r | −172r | −237 | −241 | −265 | −342 | −163 | −88 | −28 | |
| Capital expenditure | −0.6 | −0.4 | −3.9 | −1.1 | −0.2 | −10 | −5.1 | −5.9 | −4.6r | −1.6r | |
| Cash from investing activities | 262 | 71 | 163 | −189 | −48 | 288 | −60 | −389 | −97 | −70 | |
| Shares issued | — | — | — | 227 | 261 | — | — | 559 | 183r | 61r | |
| Shares bought back | — | −76 | — | — | — | — | — | — | — | — | |
| Cash from financing activities | −267 | 1.1 | −0.7 | 458 | 264 | 2.8 | 414 | 565 | 191 | 66 | |
| Exchange-rate effect on cash | −6.3 | −2.0r | 0.6r | −0.4 | −1.5 | 1.1 | −0.9 | −0.4 | — | — | |
| Change in cash | −39 | 29 | −9.1 | 32 | −27 | 26 | 11 | 13 | 6.7r | −32r | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2023
Events at Intercept Pharmaceuticals#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Debt called early 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 8 · Unregistered share sale 6 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 5
| Filed | What happened | Filing |
|---|---|---|
| Debt called earlyTaken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Unregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K |
As of Nov 8, 2023
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2012 | $30 M | No. 1 | $10 to $50 million | 2 | equity | SEC |
Lobbying by Intercept Pharmaceuticals#
$0 spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
Sidley Austin LLP
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $0 | — | 3 |
| 2025 | $0 | — | 4 |
| 2024 | $180 K | — | 4 |
| 2023 | $120 K | — | 4 |
| 2022 | $100 K | — | 4 |
FDA drug approvals: Intercept Pharmaceuticals#
2 approved applications held, 2 of them new molecular entities; 1 approvals and 0 new uses in 2026.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2020 | · | · | · | · | · | · | · | 170 | 2 | · | · | · | 172 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| effective | 2 people | LayoffWARN notice | San Diego County, California | Notice list |
| 170 people | Restructuring planSEC 8-K | “The Plan will result in a workforce reduction of approximately 25%, or approximately 170 employees.” | Filing |
How Intercept Pharmaceuticals compares in Biotechnology
- Revenue$286 M · higher than 81% of 648
- Net margin77.6% · higher than 99% of 408
- Revenue growth9.6% · higher than 53% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Intercept Pharmaceuticals🇺🇸 | $447 M | — | 77.6% | +9.6% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
How current the figures are
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2022
- Balance sheet:
- As of December-2022
- Employees:
- As on 2021
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Intercept Pharmaceuticals? Verify and update this profile — free
Show Intercept Pharmaceuticals's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.